Aldeyra Therapeutics (ALDX) Change in Account Payables (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Change in Account Payables came in at -$17105.0 in Q1 2026, down 110.32% YoY from $165693.0 in Q1 2025, and down 111.79% on a QoQ basis from $145038.0 in Q4 2025.
Aldeyra Therapeutics (ALDX) Change in Account Payables (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Change in Account Payables data on file, last reported at -$17105.0 in Q1 2026.
- Quarterly Change in Account Payables fell 110.32% year-over-year to -$17105.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$204790.0 (down 411.01% YoY) and the FY2025 annual result came in at -$21992.0, up 98.1% from the prior year.
- Change in Account Payables eased to -$17105.0 in Q1 2026, from $145038.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.4 million in Q1 2022 to a low of -$1.2 million in Q4 2022.
- A 5-year average of -$51667.4 and a median of -$23622.0 in 2023 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 2742.12% in 2025, down 1405.01% in 2025.
- Tracing ALDX's Change in Account Payables over 5 years: stood at -$1.2 million in 2022, then jumped by 192.97% to $1.1 million in 2023, then slumped by 100.59% to -$6466.0 in 2024, then jumped by 2343.09% to $145038.0 in 2025, then sank by 111.79% to -$17105.0 in 2026.
- The last three Change in Account Payables figures came in at -$17105.0 (Q1 2026), $145038.0 (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | -3,880.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,880.00 |
| Jun 30, 2026 | -3,880.00 |
| Mar 31, 2026 | -17,105.00 |
| Mar 31, 2026 | -17,105.00 |
| Dec 31, 2025 | 145,038.00 |
| Dec 31, 2025 | 145,038.00 |
| Sep 30, 2025 | -1.02 Mn |
| Sep 30, 2025 | -1.02 Mn |
| Jun 30, 2025 | 683,384.00 |
| Jun 30, 2025 | 683,384.00 |
| Mar 31, 2025 | 165,693.00 |
| Mar 31, 2025 | 165,693.00 |
| Dec 31, 2024 | -6,466.00 |
| Dec 31, 2024 | -6,466.00 |
| Sep 30, 2024 | -67,515.00 |
| Sep 30, 2024 | -67,515.00 |
| Jun 30, 2024 | -25,865.00 |
| Jun 30, 2024 | -25,865.00 |
| Mar 31, 2024 | -1.06 Mn |
| Mar 31, 2024 | -1.06 Mn |